

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Fig. S1. Effects of EGFR-TKIs on carvacrol-induced cytokines expression. Relative mRNA levels of IL-6 and IL-8 in HaCaT cells treated with 100 μ M carvacrol (Car) in the absence and presence of gefitinib (GEF) (A-B) or afatinib (AFA) (C-D) at different concentrations for 3 hrs. Data were normalized to the vehicle control. * $P < 0.05$, ** $P < 0.01$, vs. vehicle; ## $P < 0.01$ vs. carvacrol (Car) by one-way ANOVA followed by Dunnett's multiple comparison tests.




Fig. S2. Effects of MK-2206 on carvacrol-induced cytokines expression. Relative mRNA levels of IL-6 (A) and IL-8 (B) in HaCaT cells treated with 100 μ M carvacrol (Car) in the absence and presence of MK-2206 (100 nM). Data were normalized to the vehicle (Veh) control. ** $P < 0.01$, vs. vehicle (Veh); ## $P < 0.01$ vs. carvacrol (Car) by one-way ANOVA followed by Dunnett's multiple comparison tests.




Fig. S3. Erlotinib has no effect on healthy skin. (A-B) Representative images of the gross appearance (A) and H&E-stained sections (B) of the back skins of WT C57BL/6J mice treated with 2.0 mg/kg erlotinib (ERT). (C) Quantification of epidermal thickness in mice of the indicated group. All bar graphs represent mean \pm SEM (N = 5 mice). ^{ns} $P > 0.05$, vs. vehicle (Veh) by unpaired t tests.

